Highlights of This Issue 5369

SPECIAL FEATURES

Highly Active Antitumor Therapy (HAATT) for Epidermal Growth Factor Receptor–Mutant Lung Cancer
Juliann Chmielecki and William Pao
See article p. 5489

Target of Rapamycin Signaling in Leukemia and Lymphoma
Collin Vu and David A. Fruman

Phase III Clinical Trial Development: A Process of Chutes and Ladders
David M. Dilts, Steven K. Cheng, Joshua S. Crites, Alan B. Sandler, and James H. Doroshow
See article p. 5557

HUMAN CANCER BIOLOGY

Hypoexpression and Epigenetic Regulation of Candidate Tumor Suppressor Gene CADM-2 in Human Prostate Cancer
Guimin Chang, Shuping Xu, Rajiv Dhir, Uma Chandran, Denise S. O'Keefe, Norman M. Greenberg, and Jeffrey R. Gingrich

MSH6 and MUTYH Deficiency Is a Frequent Event in Early-Onset Colorectal Cancer
Maria Dolores Giráldez, Francesc Balaguer, Luis Bujanda, Miriam Cuatrecasas, Jennifer Muñoz, Virginia Alonso-Espinaco, Mikel Larzabal, Anna Petit, Victoria Gonzalo, Teresa Ocaña, Leticia Moreira, José María Enríquez-Navascués, C. Richard Boland, Ajay Goel, Antoni Castells, and Sergi Castellví-Bel

CANCER THERAPY: PRECLINICAL

Differential Gene Expression in Benign Prostate Epithelium of Men with and without Prostate Cancer: Evidence for a Prostate Cancer Field Effect

Dual Inhibition of PI3K and mTORC1/2 Signaling by NVP-BEZ235 as a New Therapeutic Strategy for Acute Myeloid Leukemia
Nicolas Chapuis, Jerome Tamburini, Alexa S. Green, Christine Vignon, Valerie Bardet, Aymeric Neyret, Melanie Pannetier, Lise Willems, Sophie Park, Alexandre Macone, Sauveur-Michel Maira, Norbert Ifrah, François Dreyfus, Olivier Herault, Catherine Lacombe, Patrick Mayeux, and Didier Bouscary

The Insulin-like Growth Factor I Receptor/Insulin Receptor Tyrosine Kinase Inhibitor PQIP Exhibits Enhanced Antitumor Effects in Combination with Chemotherapy Against Colorectal Cancer Models
Sara A. Flanigan, Todd M. Pitts, S. Gail Eckhardt, John J. Tentler, Aik Choon Tan, Andrew Thorburn, and Stephen Leong

Development of a Validated Immunofluorescence Assay for γH2AX as a Pharmacodynamic Marker of Topoisomerase I Inhibitor Activity
Robert J. Kinders, Melinda Hollingshead, Scott Lawrence, Jiuping Ji, Brian Tabb, William M. Bonner, Yves Pommier, Larry Rubinstein, Yvonne A. Evrard, Ralph E. Parchment, Joseph Tomaszewski, and James H. Doroshow; for the National Cancer Institute Phase 0 Clinical Trials Team
Transduction of Tumor-Specific T Cells with CXCR2 Chemokine Receptor Improves Migration to Tumor and Antitumor Immune Responses
Weiyi Peng, Yang Ye, Brian A. Rabinovich, Chengwen Liu, Yanyan Lou, Minying Zhang, Mayra Whittington, Yan Yang, Willem W. Overwijk, Gregory Lizée, and Patrick Hvu

Overexpression of High-Mobility Group Box 2 Is Associated with Tumor Aggressiveness and Prognosis of Hepatocellular Carcinoma
Jung-Hee Kwon, Jongmin Kim, Jin Young Park, Sun Mi Hong, Chang Wook Park, Seok Joo Hong, Sun Young Park, Yoon Jung Choi, In-Gu Do, Jae-Won Joh, Dae Shick Kim, and Kwan Yong Choi

Prognostic Significance of RNA-Dependent Protein Kinase on Non–Small Cell Lung Cancer Patients
Abujiang Pataer, Maria Gabriela Raso, Arlene M. Correa, Carmen Behrens, Koji Tsuta, Luisa Solis, Bingliang Fang, Jack A. Roth, Ignacio I. Wistuba, and Stephen G. Swisher

Expression, Cellular Distribution, and Prognostic Relevance of TRAIL Receptors in Hepatocellular Carcinoma
Lydia Kriegl, Andreas Jung, Jutta Engel, Christiane J. Bruns, Frank T. Kolligs, Thomas Kirchner, Burkhard Göke, and Enrico N. De Toni

Vaccination of Metastatic Renal Cancer Patients with MVA-5T4: A Randomized, Double-Blind, Placebo-Controlled Phase III Study
Robert J. Amato, Robert E. Hawkins, Howard L. Kaufman, John A. Thompson, Piotr Tomczak, Cezary Szczylik, Mike McDonald, Sarah Eastty, William H. Shingler, Jackie de Belin, Madusha Goonewardena, Stuart Naylor, and Richard Harrop

A Randomized Trial of Ex vivo CD40L Activation of a Dendritic Cell Vaccine in Colorectal Cancer Patients: Tumor-Specific Immune Responses Are Associated with Improved Survival
5557

**A Sense of Urgency: Evaluating the Link between Clinical Trial Development Time and the Accrual Performance of Cancer Therapy Evaluation Program (NCI-CTEP) Sponsored Studies**

Steven K. Cheng, Mary S. Dietrich, and David M. Dilts

See commentary p. 5381

---

5564

**REO-10: A Phase I Study of Intravenous Reovirus and Docetaxel in Patients with Advanced Cancer**

Charles Comins, James Spicer, Andrew Protheroe, Victoria Roulstone, Katie Twigger, Christine M. White, Richard Vile, Alan Melcher, Matt C. Coffey, Karl L. Mettinger, Gerard Novo, David E. Cohn, Mitch Phelps, Kevin J. Harrington, and Hardev S. Pandha

---

5573

**Combination of Temsirolimus (CCI-779) with Chemoradiation in Newly Diagnosed Glioblastoma Multiforme (GBM) (NCCTG trial N027D) Is Associated with Increased Infectious Risks**


---

5581

**PREDICTIVE BIOMARKERS AND PERSONALIZED MEDICINE**

**Optimizing the Detection of Lung Cancer Patients Harboring Anaplastic Lymphoma Kinase (ALK) Gene Rearrangements Potentially Suitable for ALK Inhibitor Treatment**

D. Ross Camidge, Scott A. Kono, Antonella Flacco, Aik-Choon Tan, Robert C. Doebele, Qing Zhou, Lucio Crino, Wilbur A. Franklin, and Mariela Varella-Garcia

---

5591

**Germline Polymorphisms in Genes Involved in the IGF1 Pathway Predict Efficacy of Cetuximab in Wild-type KRAS mCRC Patients**

Thomas Winder, Wu Zhang, Dongyun Yang, Yan Ning, Pierre Bohanes, Armin Gerger, Peter M. Wilson, Alexandra Pohl, David J. Mauro, Christiane Langer, Eric K. Rowinsky, and Heinz-Josef Lenz

---

**ABOUT THE COVER**

Atu027, a liposomal siRNA, is a novel RNAi therapeutic for cancer therapy suppressing PKN3 gene expression in endothelial cells of the vasculature. In cultured human endothelial cells (HUVEC), Atu027 mediated downregulation of PKN3 led to increased levels of the adhesion protein vascular endothelial (VE)-cadherin. The different levels of VE-cadherin protein are depicted in this image in a color-coded manner reflecting highest VE-cadherin levels as red colored membrane staining. The authors show that Atu027 treatment modulates the vascular endothelium in a way that metastasis through the blood vessels to the lung is effectively inhibited. For further details, please see Santel and colleagues on page 5469 in this issue.